drugset / Trial / NCT04358016

Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

NCT04358016

Phase 4 Completed 54 enrolled Changhai Hospital
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The investigators studied the renal function index level in terlipressin treated cirrhotic patients with upper-gastrointestinal bleeding at different time point.

Timeline

Start
2018-01-01
Primary completion
2020-01-01
Completion
2020-03-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Somatostatin Traditional medicine (herbal / TCM) 3 mg Intravenous
Subject Terlipressin Peptide 1 mg Intravenous

Indications